IO Biotech (IOBT) Price & Analysis

Compare

410 Followers

IOBT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.66 - $2.79

Previous CloseN/A

Volume57.25K

Average Volume (3M)6.15M

Market Cap

$128.47M

Enterprise Value$71.80M

Total Cash (Recent Filing)$28.13M

Total Debt (Recent Filing)$8.36M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Nov 05, 2025

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding65,880,910

10 Day Avg. Volume1,182,348

30 Day Avg. Volume6,149,199

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.56

Enterprise Value/Revenue84.47

Enterprise Value/Gross Profit-297.92

Enterprise Value/Ebitda-0.71

Forecast

1Y Price Target

$9.00

Price Target Upside361.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial PositionThe company ended 2Q25 with $28M and recently added $14.4M, which combined is expected to support operations into 1Q26.

Regulatory ApprovalCylembio, if approved, would position it as a first-in-class cancer vaccine for advanced melanoma patients.

Bears Say

Clinical Trial ResultsThe trial narrowly missed the primary endpoint of progression-free survival with a p-value of 0.056 versus the threshold of 0.045.

IO Biotech News

IO Biotech says statistical significant missed on primary endpoint for Cylembio

IO Biotech (IOBT) announces topline results from the pivotal Phase 3 trial of its investigational, immune-modulatory, off-the-shelf therapeutic...

29d ago

IOBT

IO Biotech Reports Q2 2025 Financial Results

Io Biotech, Inc. ( ($IOBT) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

IOBT

IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed

IO Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

25d ago

IOBT

Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech

IO Biotech, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from...

29d ago

IOBT

IO Biotech Reveals Phase 3 Trial Results for Cylembio

IO Biotech ( ($IOBT) ) has shared an announcement. On August 11, 2025, IO Biotech announced the topline...

29d ago

IOBT

IO Biotech files to sell 4.22M shares of common stock for holders

17:24 EDT IO Biotech (IOBT) files to sell 4.22M shares of common stock for holders Published first on...

2M ago

IOBT

IO Biotech Issues Tranche B Warrant to EIB

The latest update is out from IO Biotech ( ($IOBT) ). On June 24, 2025, IO Biotech issued...

2M ago

IOBT

IO Biotech Amends CEO Service Agreement

IO Biotech ( ($IOBT) ) has issued an announcement. On June 19, 2025, IO Biotech ApS, a subsidiary...

3M ago

IOBT

IO Biotech Elects New Director at Annual Meeting

The latest update is out from IO Biotech ( ($IOBT) ). On June 5, 2025, IO Biotech, Inc....

3M ago

IOBT

IO Biotech Regains Nasdaq Compliance with Stock Price

IO Biotech ( ($IOBT) ) has issued an update. IO Biotech, Inc. faced a compliance issue with Nasdaq’s...

3M ago

IOBT

IO Biotech files to sell 5.62M shares of common stock for holders

The company will not receive any of the proceeds from the sale of its common stock by the...

4M ago

IOBT

IO Biotech Advances Cancer Vaccine Trials in Q1 2025

Io Biotech, Inc. ( ($IOBT) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

IOBT

IO Biotech: Promising Future with Strong Clinical Progress and Financial Backing

TD Cowen analyst Yaron Werber has maintained their bullish stance on IOBT stock, giving a Buy rating today....

4M ago

IOBT

IO Biotech price target raised to $14 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a...

4M ago

IOBT

IOBT FAQ

What was IO Biotech’s price range in the past 12 months?

IO Biotech lowest stock price was $0.66 and its highest was $2.79 in the past 12 months.

What is IO Biotech’s market cap?

IO Biotech’s market cap is $128.47M.

When is IO Biotech’s upcoming earnings report date?

IO Biotech’s upcoming earnings report date is Nov 05, 2025 which is in 57 days.

How were IO Biotech’s earnings last quarter?

IO Biotech released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.356 by -$0.044.

Is IO Biotech overvalued?

According to Wall Street analysts IO Biotech’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does IO Biotech pay dividends?

IO Biotech does not currently pay dividends.

What is IO Biotech’s EPS estimate?

IO Biotech’s EPS estimate is -0.35.

How many shares outstanding does IO Biotech have?

IO Biotech has 65,880,910 shares outstanding.

What happened to IO Biotech’s price movement after its last earnings report?

IO Biotech reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.356. Following the earnings report the stock price went up 68.75%.

Which hedge fund is a major shareholder of IO Biotech?

Among the largest hedge funds holding IO Biotech’s share is RA Capital Management. It holds IO Biotech’s shares valued at 0.

IO Biotech Stock Smart Score

Neutral

Fundamentals

Return on Equity

-212.51%

Trailing 12-Months

Asset Growth

-62.03%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

IO Biotech

IO Biotech (IOBT) is a biotechnology company focused on the development of immune-modulating cancer therapies. The company leverages its proprietary T-win technology platform to create novel immune therapies intended to treat various types of cancer by activating the immune system against tumor cells. IO Biotech operates within the pharmaceutical and biotechnology sector, working towards innovative solutions to improve cancer treatment outcomes.

IO Biotech (IOBT) Earnings & Revenues

Historic Earnings Reports

IOBT Stock 12 Month Forecast

Average Price Target

$9.00

▲(361.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","7":"$7","11":"$11","15":"$15","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,3,7,11,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,3.126153846153846,4.032307692307692,4.938461538461539,5.844615384615384,6.750769230769231,7.656923076923077,8.563076923076922,9.46923076923077,10.375384615384615,11.281538461538462,12.187692307692307,13.093846153846153,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,2.741538461538462,3.263076923076923,3.7846153846153845,4.306153846153846,4.827692307692308,5.349230769230769,5.8707692307692305,6.392307692307693,6.913846153846153,7.435384615384615,7.956923076923077,8.478461538461538,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,2.356923076923077,2.493846153846154,2.6307692307692307,2.767692307692308,2.9046153846153846,3.0415384615384617,3.1784615384615384,3.315384615384615,3.4523076923076923,3.5892307692307694,3.726153846153846,3.863076923076923,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.87,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.8,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.76,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >